William Gerhart

William Gerhart

William Gerhart

Vice Chair
CEO, Respivant Sciences, Inc.

William Gerhart's Bio

William Gerhart is a biotech entrepreneur with a successful track record of developing important new medicines that ultimately gain regulatory approval to benefit patients with respiratory diseases. Mr. Gerhart is currently the CEO of Respivant Sciences, a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of patients suffering from respiratory diseases.  

Prior to Respivant, Mr. Gerhart was a founder and the CEO of Patara Pharma from 2014 to 2018, which conducted the early development of a new inhaled therapy for patients with idiopathic pulmonary fibrosis, acquired by Respivant. Prior to Patara, he was the President & CEO of Elevation Pharmaceuticals, a San Diego-based biotech he co-founded in 2008 that developed a new inhaled therapy for patients with severe chronic obstructive pulmonary disease (COPD). Elevation was acquired in 2012 by Sunovion, a subsidiary of Dainippon Sumitomo Pharma, and in 2017 the FDA approved this new therapy, now marketed as Lonhala® Magnair® – the first nebulized long-acting muscarinic antagonist (LAMA) for COPD patients. Prior to Elevation, Mr. Gerhart was the President and CEO of Mpex Pharmaceuticals from 2002 to 2007, a company he co-founded to discover and develop new antibacterials for the treatment of serious infections, including Quinsair®, an inhaled antibiotic now approved in Europe and Canada for the treatment of cystic fibrosis.

Mr. Gerhart received his MBA from Harvard Business School and his BBA degree from Baylor University.

general accessory